GB201502110D0 - Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function - Google Patents

Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function

Info

Publication number
GB201502110D0
GB201502110D0 GB201502110A GB201502110A GB201502110D0 GB 201502110 D0 GB201502110 D0 GB 201502110D0 GB 201502110 A GB201502110 A GB 201502110A GB 201502110 A GB201502110 A GB 201502110A GB 201502110 D0 GB201502110 D0 GB 201502110D0
Authority
GB
United Kingdom
Prior art keywords
treatment
cystic fibrosis
conditions associated
ion channel
channel function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201502110A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Algipharma AS
Original Assignee
Algipharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algipharma AS filed Critical Algipharma AS
Priority to GB201502110A priority Critical patent/GB201502110D0/en
Priority to US15/121,671 priority patent/US20160361342A1/en
Priority to RU2016136449A priority patent/RU2016136449A/en
Priority to EP15708474.0A priority patent/EP3110426A1/en
Priority to JP2016554405A priority patent/JP2017510563A/en
Priority to CA2940560A priority patent/CA2940560A1/en
Priority to KR1020167026840A priority patent/KR20160119259A/en
Priority to AU2015222051A priority patent/AU2015222051A1/en
Priority to PCT/EP2015/054207 priority patent/WO2015128495A1/en
Priority to CN201580010273.7A priority patent/CN106029079A/en
Publication of GB201502110D0 publication Critical patent/GB201502110D0/en
Ceased legal-status Critical Current

Links

GB201502110A 2014-02-28 2015-02-09 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function Ceased GB201502110D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB201502110A GB201502110D0 (en) 2015-02-09 2015-02-09 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function
US15/121,671 US20160361342A1 (en) 2014-02-28 2015-02-27 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
RU2016136449A RU2016136449A (en) 2014-02-28 2015-02-27 APPLICATION OF ALGINATE OLIGOMETES IN THE TREATMENT OF MUKOVISCIDOSIS AND OTHER CONDITIONS ASSOCIATED WITH THE DISTURBED FUNCTION OF CFTR ION CHANNELS
EP15708474.0A EP3110426A1 (en) 2014-02-28 2015-02-27 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
JP2016554405A JP2017510563A (en) 2014-02-28 2015-02-27 Use of alginate oligomers in the treatment of cystic fibrosis and other pathologies associated with defective CFTR ion channel function
CA2940560A CA2940560A1 (en) 2014-02-28 2015-02-27 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
KR1020167026840A KR20160119259A (en) 2014-02-28 2015-02-27 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
AU2015222051A AU2015222051A1 (en) 2014-02-28 2015-02-27 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function
PCT/EP2015/054207 WO2015128495A1 (en) 2014-02-28 2015-02-27 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
CN201580010273.7A CN106029079A (en) 2014-02-28 2015-02-27 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201502110A GB201502110D0 (en) 2015-02-09 2015-02-09 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function

Publications (1)

Publication Number Publication Date
GB201502110D0 true GB201502110D0 (en) 2015-03-25

Family

ID=52746344

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201502110A Ceased GB201502110D0 (en) 2014-02-28 2015-02-09 Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function

Country Status (1)

Country Link
GB (1) GB201502110D0 (en)

Similar Documents

Publication Publication Date Title
EP3634288A4 (en) Electrode cured and manufactured in the body, and related methods and devices
IL267685A (en) Method for modulating inflammasome activity and inflammation in the lung
EP3303634A4 (en) Cas9 variants and methods of use thereof
EP3359644A4 (en) Novel rna-guided nucleases and uses thereof
GB201504878D0 (en) Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
IL250718A0 (en) Treatment of inflammation, respiratory tract infections and cystic fibrosis
EP3200808A4 (en) Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP2968285A4 (en) Compounds and methods for the treatment of cystic fibrosis
SG10201606961TA (en) Quantum-dot spectrometers for use in biomedical devices and methods of use
HK1256419A1 (en) Acetamide thienotriazolodiazepines and uses thereof
EP3355983A4 (en) Dry eye treatment devices and methods
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
EP3296325A4 (en) Elliptical, needle-shaped, or rod-shaped crosslinked polymer particles, and use thereof
EP3139949A4 (en) Methods and compositions for treating cystic fibrosis
IL267639A (en) Oncolytic viruses and therapeutic molecules
EP3193875A4 (en) Levocetirizine and montelukast in the treatment of inflammation mediated conditions
EP3463324A4 (en) Levocetirizine and montelukast in the treatment of radiation-mediated conditions
HK1257679A1 (en) Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
EP3243382A4 (en) Waterless livewell apparatus and refrigeration appliance provided with the waterless livewell apparatus
EP3302207A4 (en) Surface treatment apparatuses and methods
EP3166626A4 (en) Materials and methods for treating disorders associated with sulfatase enzymes
ZA201708223B (en) Endostatin fragments and variants for use in treating fibrosis
IL270701A (en) Neurotrophins for use in the treatment of hearing loss
EP3331488A4 (en) Improved hyaluronan and modified-hyaluronan in biomedical applications
EP3458157A4 (en) Methods for treating disorders associated with fibrosis and systemic sclerosis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)